These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 23782054)

  • 1. Prevalence of human immunodeficiency virus RNA and antibody in first-time, lapsed, and repeat blood donations across five international regions and relative efficacy of alternative screening scenarios.
    Bruhn R; Lelie N; Custer B; Busch M; Kleinman S;
    Transfusion; 2013 Oct; 53(10 Pt 2):2399-412. PubMed ID: 23782054
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relative efficacy of nucleic acid amplification testing and serologic screening in preventing hepatitis C virus transmission risk in seven international regions.
    Bruhn R; Lelie N; Busch M; Kleinman S;
    Transfusion; 2015 Jun; 55(6):1195-205. PubMed ID: 25727549
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of individual-donation nucleic acid testing on risk of human immunodeficiency virus, hepatitis B virus, and hepatitis C virus transmission by blood transfusion in South Africa.
    Vermeulen M; Lelie N; Sykes W; Crookes R; Swanevelder J; Gaggia L; Le Roux M; Kuun E; Gulube S; Reddy R
    Transfusion; 2009 Jun; 49(6):1115-25. PubMed ID: 19309474
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of human immunodeficiency virus assays in window phase and elite controller samples: viral load distribution and implications for transmission risk.
    Vermeulen M; Coleman C; Mitchel J; Reddy R; van Drimmelen H; Fickett T; Busch M; Lelie N
    Transfusion; 2013 Oct; 53(10 Pt 2):2384-98. PubMed ID: 23445273
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduction of the risk of transfusion-transmitted viral infection by nucleic acid amplification testing in the Western Cape of South Africa: a 5-year review.
    Cable R; Lelie N; Bird A
    Vox Sang; 2013 Feb; 104(2):93-9. PubMed ID: 22924987
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Human immunodeficiency virus prevalence, incidence, and residual transmission risk in first-time and repeat blood donations in Zimbabwe: implications on blood safety.
    Mapako T; Mvere DA; Chitiyo ME; Rusakaniko S; Postma MJ; van Hulst M
    Transfusion; 2013 Oct; 53(10 Pt 2):2413-21. PubMed ID: 23789991
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trends in prevalence, incidence, and residual risk of major transfusion-transmissible viral infections in United Arab Emirates blood donors: impact of individual-donation nucleic acid testing, 2004 through 2009.
    Al Shaer L; AbdulRahman M; John TJ; AlHashimi A
    Transfusion; 2012 Nov; 52(11):2300-9. PubMed ID: 22691239
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A new strategy for estimating risks of transfusion-transmitted viral infections based on rates of detection of recently infected donors.
    Busch MP; Glynn SA; Stramer SL; Strong DM; Caglioti S; Wright DJ; Pappalardo B; Kleinman SH;
    Transfusion; 2005 Feb; 45(2):254-64. PubMed ID: 15660836
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Experience of German Red Cross blood donor services with nucleic acid testing: results of screening more than 30 million blood donations for human immunodeficiency virus-1, hepatitis C virus, and hepatitis B virus.
    Hourfar MK; Jork C; Schottstedt V; Weber-Schehl M; Brixner V; Busch MP; Geusendam G; Gubbe K; Mahnhardt C; Mayr-Wohlfart U; Pichl L; Roth WK; Schmidt M; Seifried E; Wright DJ;
    Transfusion; 2008 Aug; 48(8):1558-66. PubMed ID: 18466173
    [TBL] [Abstract][Full Text] [Related]  

  • 10. First report of human immunodeficiency virus transmission via an RNA-screened blood donation.
    Delwart EL; Kalmin ND; Jones TS; Ladd DJ; Foley B; Tobler LH; Tsui RC; Busch MP
    Vox Sang; 2004 Apr; 86(3):171-7. PubMed ID: 15078251
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Viremia levels in hepatitis C infection among Egyptian blood donors and implications for transmission risk with different screening scenarios.
    El Ekiaby M; Moftah F; Goubran H; van Drimmelen H; LaPerche S; Kleinman S; Busch M; Lelie N
    Transfusion; 2015 Jun; 55(6):1186-94. PubMed ID: 25766141
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Residual risk of transfusion-transmitted viral infections in Shenzhen, China, 2001 through 2004.
    Shang G; Seed CR; Wang F; Nie D; Farrugia A
    Transfusion; 2007 Mar; 47(3):529-39. PubMed ID: 17319836
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Estimated rate of HIV-1-infectious but seronegative blood donations in Bangkok, Thailand.
    Kitayaporn D; Kaewkungwal J; Bejrachandra S; Rungroung E; Chandanayingyong D; Mastro TD
    AIDS; 1996 Sep; 10(10):1157-62. PubMed ID: 8874634
    [TBL] [Abstract][Full Text] [Related]  

  • 14. How safe is safe: new human immunodeficiency virus Type 1 variants missed by nucleic acid testing.
    Müller B; Nübling CM; Kress J; Roth WK; De Zolt S; Pichl L
    Transfusion; 2013 Oct; 53(10 Pt 2):2422-30. PubMed ID: 23782012
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Failure and success of HIV tests for the prevention of HIV-1 transmission by blood and tissue donations.
    Najioullah F; Barlet V; Renaudier P; Guitton C; Crova P; Guérin JC; Peyramond D; Trabaud MA; Coudurier N; Tardy JC; André P
    J Med Virol; 2004 Jul; 73(3):347-9. PubMed ID: 15170627
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The persistence of hepatitis C virus transmission risk in China despite serologic screening of blood donations.
    Wang J; Liu J; Huang Y; Wright DJ; Li J; Zhou Z; He W; Yang T; Yao F; Zhu X; Wen G; Bi X; Tiemuer MH; Wen X; Huang M; Cao R; Yun Z; Lü Y; Ma H; Guo N; Yu Q; Ness P; Shan H;
    Transfusion; 2013 Oct; 53(10 Pt 2):2489-97. PubMed ID: 23781978
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Trends in residual risk of transfusion-transmitted viral infections (HIV, HCV, HBV) in France between 1992 and 2002 and impact of viral genome screening (Nucleic Acid Testing)].
    Pillonel J; Laperche S; ; ;
    Transfus Clin Biol; 2004 Apr; 11(2):81-6. PubMed ID: 15120104
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A modeling framework for evaluation and comparison of trigger strategies for switching from minipool to individual-donation testing for West Nile virus.
    Biggerstaff BJ; Petersen LR
    Transfusion; 2009 Jun; 49(6):1151-9. PubMed ID: 19309472
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human immunodeficiency virus-1 and hepatitis C virus RNA among South African blood donors: estimation of residual transfusion risk and yield of nucleic acid testing.
    Fang CT; Field SP; Busch MP; Heyns Adu P
    Vox Sang; 2003 Jul; 85(1):9-19. PubMed ID: 12823725
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Should HBV DNA NAT replace HBsAg and/or anti-HBc screening of blood donors?
    Busch MP
    Transfus Clin Biol; 2004 Feb; 11(1):26-32. PubMed ID: 14980546
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.